Almost every microcap story eventually becomes a financing story. A company signs a contract, then has to raise the money to deliver it, and the raise takes a slice of the company. That is the ordinary arithmetic of this end of the market, and it is why share count matters more here than almost anywhere else.
Federal funding breaks that pattern. A loan from the Export-Import Bank, a development award from a defense agency, or a procurement contract from a stockpile program is capital that arrives without issuing a share. The industry term is non-dilutive. It is also, usually, slow, conditional and smaller than the project it supports, which is why the presence of federal money is a starting point for analysis rather than a conclusion.
The five below all have documented federal involvement. Each entry states what kind, because a $25 million loan, an $8 million investment and a repeated development award are three different things.
Ordering: alphabetical by ticker. The order implies nothing about merit, quality, or prospects.
Price data: figures were pulled between August 6 and September 22, 2026, and each entry states its own date. They are not a single simultaneous snapshot.
Airship AI Holdings (NASDAQ: AISP)
Federal agencies as customers rather than funders, which is the version that shows up as revenue.
Airship AI sells AI-driven video, sensor and data management systems, primarily to US government agencies. Its Outpost AI hardware processes video at the camera rather than shipping it to a data center, which matters where bandwidth is limited and chain of custody is a legal requirement.
The federal link: procurement. Agencies buy the product, so federal money reaches this company as revenue rather than as grant funding. Per second quarter results released August 6, 2026, revenue was $4.12 million with gross profit of $3.09 million, a 75% gross margin.
Key risk: the same concentration works in reverse. A procurement freeze or a budget delay removes revenue that a commercial customer base would have spread across many buyers. The company also filed a $100 million mixed securities shelf on May 11, 2026, which against this market value is a large standing authorization to issue.
5E Advanced Materials (NASDAQ: FEAM)
An $8 million federal investment against a project that costs orders of magnitude more.
5E is developing the Fort Cady boron and lithium project in California’s Mojave Desert. Boron is used in glass, ceramics, agriculture and permanent magnets, and US domestic production is limited. The company is pre-revenue.
The federal link: an $8 million investment from the Export-Import Bank announced August 10, 2026, with Fort Cady named in the administration’s critical minerals initiative announced at a White House roundtable on August 7, 2026. Reuters reported the broader package at about $3 billion.
Key risk: the dilution behind the validation. Shares outstanding rose 519% over one year to 41.52 million. Trailing net loss is $43.43 million against no revenue, free cash flow is negative $28.07 million, and the share price has fallen 55% over the trailing 52 weeks. An $8 million federal investment is real endorsement and a small fraction of what building Fort Cady requires.
Lightbridge Corporation (NASDAQ: LTBR)
A national laboratory doing the testing, and almost the entire market value sitting in cash.
Lightbridge develops metallic nuclear fuel: a uranium-zirconium alloy extruded into a helically twisted shape, intended to replace the conventional ceramic pellet in water-cooled reactors. It is pre-revenue and has been since before its 2009 renaming from Thorium Power.
The federal link: a framework agreement with Idaho National Laboratory covering irradiation testing. The federal contribution here is capability rather than cash: physical testing of nuclear fuel cannot be done commercially at this scale. The company received a Japan Patent Office notice of allowance on September 1, 2026.
Key risk: cash reserves of $237.5 million against a $241.02 million market capitalization at the September 25, 2026 close means the balance sheet is now worth almost the entire company, and the market is assigning close to nothing to the fuel program itself. That cash arrived by issuing shares: the count rose 72.75% over one year to 35.23 million. Short interest stands at 12.31%. Thirteen employees.
MediWound (NASDAQ: MDWD)
Two separate federal agencies, repeatedly, across administrations.
MediWound makes enzymatic products that remove dead tissue without surgery. NexoBrid is an FDA-approved topical gel that clears burn eschar in a single four-hour bedside application, approved in 45 countries and held in the US Strategic National Stockpile. EscharEx, aimed at chronic wounds, is in a Phase III trial.
The federal link: the deepest on this list. On September 22, 2026 the Department of War awarded an additional $3.3 million to develop a room-temperature-stable NexoBrid formulation, bringing that program to $21.8 million from $14.4 million at the end of 2023. Separately, per the April 2, 2026 release, BARDA awarded distributor Vericel a ten-year contract valued at up to $197 million against a $35 million base period.
Key risk: the revenue is going the wrong way. Trailing revenue is $11.86 million, down 40.3%, while full-year guidance of $24 million to $26 million has been reaffirmed. First half revenue was $6.05 million, so the second half must produce roughly three times the first. Second quarter loss per share was $1.36 against a 77 cent consensus.
Westwater Resources (NYSE American: WWR)
A $25 million federal loan against a $115 million funding gap, and an equity facility larger than the company.
Westwater is building the first vertically integrated domestic supply of battery-grade natural graphite, the material that forms the anode inside a lithium-ion battery. Its Coosa deposit in Alabama is described by the company as the largest natural flake graphite deposit in the contiguous United States. It is pre-revenue.
The federal link: an Export-Import Bank loan of $25 million approved August 10, 2026, plus FAST-41 covered project designation for Coosa on March 31, 2026, which places it on the federal permitting dashboard with coordinated agency timelines. A Section 404 permit application went to the US Army Corps of Engineers on June 15, 2026.
Key risk: Phase I carries a $245 million cost estimate with roughly $115 million still to spend, against cash of $38.20 million at June 30, 2026 and the $25 million approval. The company retains $96.8 million of combined availability across its at-the-market and Lincoln Park equity facilities, which exceeds its entire market capitalization. Both disclosed customer agreements have been terminated: SK On in March 2026 and FCA in November 2025.
How To Research Names Like These
Divide the federal amount by the project cost before deciding what it means. This single calculation separates validation from funding. Westwater’s $25 million against roughly $115 million of remaining Phase I cost is about 22%. 5E’s $8 million against Fort Cady is a far smaller fraction. Neither is a criticism. Both mean the balance arrives from somewhere else, and that somewhere is usually equity.
Work out which kind of federal money it is. A procurement contract is revenue and appears on the income statement. A development award funds specific work and may appear as revenue or as an offset to expense. A loan is debt and has to be repaid. A permitting designation is neither, it is a schedule. These are four different facts and press releases tend to describe all of them as support.
Then check the share count anyway. Non-dilutive funding reduces the need for equity, it does not remove it. 5E’s count rose 519% in a year and Lightbridge’s rose 72.75%, both while federal relationships were in place. Track shares outstanding across four quarterly filings regardless of what the funding announcements say.
Read the standing authorizations. A shelf registration or an at-the-market facility tells you how a raise would be executed. Airship AI has a $100 million shelf against a $66.64 million market value. Westwater has $96.8 million of equity capacity against $78.60 million. Neither obliges the company to issue. Both describe what could happen without further approval.
Remember that policy is an input, not a floor. Every valuation here embeds an assumption about the durability of federal support for domestic supply chains and stockpile readiness. That support runs on appropriation cycles and has a political dimension. It is not a covenant.
This is a watchlist, not a set of recommendations, and it is not ranked. Verify every figure against current filings and live market data before acting on any of it.
Disclosure
This article is independent editorial content and reflects the author's opinion and analysis as of the date of publication. It is not investment advice and should not be relied on as the basis for any investment decision. MicroCap Desk and its contributors received no compensation of any kind — cash, securities, or otherwise — from any company mentioned, or from any third party, in connection with this article. The author holds no position in any security mentioned. Information is drawn from sources believed reliable but is not guaranteed accurate or complete. Microcap securities carry a high risk of loss. Do your own research. See our full Disclosure.
